Drug

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS
Clinical trial filingsRare / orphan disease drugs

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Pharmaceutical Holding Group Co., Ltd. (WEPON) (SHE: 002082) announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding its plan to conduct a…

NMPA Grants Priority Review to Hengrui's Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

NMPA Grants Priority Review to Hengrui’s Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationCVD

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

ADC / XDCCancer

Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism

ADC / XDCCancer

Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

ADC / XDCBiocytogen Pharmaceuticals

Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors

Show More